HCM
PMCB icon

Highlander Capital Management’s PharmaCyte Biotech PMCB Stock Holding History

Highlander Capital Management’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$33 Hold
14
– – ﹤0.01% 933
2023
Q4 		$30 Hold
14
– – ﹤0.01% 967
2023
Q3 		$0 Buy
+14
New +$36 ﹤0.01% 929

Other funds holding PMCB

KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $187M AUM 179.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Highlander Capital Management's PMCB Position: Q1 2024 in Review

Highlander Capital Management held its PharmaCyte Biotech (PMCB) position steady in Q1 2024 at 14 shares worth $33. The position accounts for ﹤0.01% of the portfolio, ranked #933.

Highlander Capital Management first reported a position in PMCB in Q3 2023 and has held it in 3 quarters since. 29 funds tracked by Wall St. Rank hold PMCB as of Q1 2024.

  • Highlander Capital Management held 14 shares of PharmaCyte Biotech worth $33 as of Q1 2024.
  • Highlander Capital Management left its PharmaCyte Biotech share count unchanged in Q1 2024.
  • PharmaCyte Biotech made up ﹤0.01% of Highlander Capital Management's portfolio in Q1 2024, its #933 holding.
  • Highlander Capital Management first reported a position in PharmaCyte Biotech in Q3 2023 and has held it in 3 quarters since.
  • 29 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2024.

Based on Highlander Capital Management's 13F filing for Q1 2024, filed 20 May 2024.